New hope for Early-Stage CLL: can a drug combo stop progression?

NCT ID NCT03516617

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This study compares two treatments for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. One group gets acalabrutinib alone, the other gets acalabrutinib plus obinutuzumab. The goal is to see which approach leads to a deeper remission with no detectable cancer cells. About 120 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.